Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Fresnillo FY net profits surge nearly 300pc

(Sharecast News) - Mining firm Fresnillo posted a solid set of interim results on Tuesday, with higher precious metal prices and disciplined cost control driving a sharp improvement in profitability. Fresnillo said robust gold output and operational efficiencies had helped offset weaker silver volumes and a non-cash hit of $133m after tax from the termination of its Silverstream contract.

Revenues rose 30.1% year-on-year to $1.93bn, while underlying earnings more than doubled, and net profits surged 297.3% to $467.6m, supported by a 16.7% drop in cost of sales and a 20% reduction in production costs.

Gold production climbed 15.9%, led by a strong performance at its Herradura mine, while silver output fell 11.7% due to mine closures and lower grades.

Fresnillo declared an interim dividend of USD 20.8 cents per share, up from USD 6.4 cents last year and raised its FY gold guidance but trimmed its silver outlook.

CEO Octavio Alvídrez said: "Our profitability has significantly improved, driven not only by favourable precious metals prices but also by a consistent operational performance and rigorous cost discipline. This has led to a substantial free cash flow generation. Our balance sheet remains robust, with ample liquidity, allowing us to declare an interim dividend of USD 20.8 cents per share in line with our policy."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.